Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHRS GH Research	$12.76 -0.5%	$10.73	$6.00 ▼ $20.50	$663.88M	0.97	187,917 shs	146,854 shs
SANA Sana Biotechnology	$2.59 +2.0%	$1.96	$1.26 ▼ $7.40	$583.99M	1.78	3.55 million shs	2.48 million shs
TLSA Tiziana Life Sciences	$1.55 +9.2%	$1.30	$0.63 ▼ $1.91	$181.11M	-0.09	472,758 shs	1.05 million shs
TRVI Trevi Therapeutics	$6.09 -1.3%	$6.29	$2.36 ▼ $7.48	$723.70M	0.59	1.35 million shs	1.14 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHRS GH Research	-0.55%	+2.08%	+27.86%	+16.00%	+3.40%
SANA Sana Biotechnology	+1.97%	-8.80%	+45.51%	-11.60%	-62.02%
TLSA Tiziana Life Sciences	+9.15%	+8.39%	+6.90%	-1.27%	+89.93%
TRVI Trevi Therapeutics	-1.30%	-13.74%	-1.62%	-9.78%	+114.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHRS GH Research	1.7719 of 5 stars	3.5	0.0	2.9	2.5	0.0
SANA Sana Biotechnology	1.9266 of 5 stars	3.4	0.0	1.6	3.3	0.6
TLSA Tiziana Life Sciences	0.9778 of 5 stars	0.0	5.0	2.0	1.7	0.0
TRVI Trevi Therapeutics	3.654 of 5 stars	4.7	2.0	3.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHRS GH Research	3.00	Buy	$32.00	150.78% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	316.99% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A
TRVI Trevi Therapeutics	3.33	Buy	$20.29	233.10% Upside

Current Analyst Ratings Breakdown

Latest TLSA, GHRS, SANA, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/19/2025	TRVI Trevi Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $20.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.05 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHRS GH Research	-$35.59M	-$0.79	N/A	N/A	N/A	N/A	-20.29%	-19.49%	9/2/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	8/6/2025 (Estimated)
TLSA Tiziana Life Sciences	-$17.69M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	8/14/2025 (Estimated)

Latest TLSA, GHRS, SANA, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHRS GH Research	N/A	15.83	15.83
SANA Sana Biotechnology	N/A	4.47	4.47
TLSA Tiziana Life Sciences	N/A	0.85	N/A
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHRS GH Research	56.90%
SANA Sana Biotechnology	88.23%
TLSA Tiziana Life Sciences	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
GHRS GH Research	41.60%
SANA Sana Biotechnology	30.10%
TLSA Tiziana Life Sciences	39.82%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	63.43 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	58.13 million	Optionable

TLSA, GHRS, SANA, and TRVI Headlines

Recent News About These Companies

Leerink Partnrs Has Bullish Forecast for TRVI Q2 Earnings

June 13 at 5:50 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

June 9, 2025 | marketbeat.com

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 9, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

June 8, 2025 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

June 4, 2025 | americanbankingnews.com

Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $18.63

June 4, 2025 | americanbankingnews.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's Why

June 3, 2025 | marketbeat.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?

June 2, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital

June 2, 2025 | marketbeat.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

June 1, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TRVI Q2 Earnings

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, GHRS, SANA, and TRVI Company Descriptions

GH Research NASDAQ:GHRS

$12.76 -0.07 (-0.55%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$12.74 -0.02 (-0.16%)

As of 06/13/2025 04:04 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Sana Biotechnology NASDAQ:SANA

$2.59 +0.05 (+1.97%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.58 0.00 (-0.19%)

As of 06/13/2025 07:15 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Tiziana Life Sciences NASDAQ:TLSA

$1.55 +0.13 (+9.15%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.59 +0.04 (+2.84%)

As of 06/13/2025 07:57 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Trevi Therapeutics NASDAQ:TRVI

$6.09 -0.08 (-1.30%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.15 +0.06 (+0.97%)

As of 06/13/2025 07:56 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time